Who is speaking
Our carefully researched speaker programmes are further enhanced by the opportunity for the delegates and speakers to discuss topics of interest in more detail during panel and round table discussions. This means that the attendees not only benefit from the expertise of the high level speaker panel but also that of the other delegates.
If you have a cutting edge case study or a presentation and would like to join the speaker panel at one of our events, please contact Mike Burden at m.burden@oxfordglobal.co.uk
Confirmed speakers
- Brian Abbott,
Director, Regulatory Affairs, AstraZeneca - Lakshmi Amaravadi,
Director Translational Medicine, Biogen - Richard Barker,
Author of '2030 - the Future of Medicine' and Chairman of Stem Cells for Safer Medicine. Former Director General at Association of the British Pharmaceutical Industry - Anne-Christine Bay-Jensen,
Group Manager, Cartilage Biology and Biomarkers, Nordic Bioscience - Tim Behrens,
Senior Director Immunology, Diagnostics and Biomarkers, Genentech - Darcey Black,
Head, Translational Research, Grunenthal Innovation - Mark Broenstrup,
Director Biomarker and Diagnostics, Sanofi Aventis - Arijit Chakravarty,
Senior Scientist, Millennium Pharmaceuticals - Michele Cleary,
Executive Director Molecular Biomarkers, Merck & Co. Inc - Mark Day,
Associate Director & Head of Translational Imaging, Abbott - Enrico Domenici,
Biomarker & Pathway Analysis Area Head for CNS, Pharma Research & Early Development, Translational Research Sciences, F. Hoffmann-La Roche Ltd - Nicholas Dracopoli,
Vice President, Biomarkers, Ortho Biotech Oncology R&D, Centocor Research & Development, Johnson & Johnson - Darragh Duffy,
Project Manager, Immunobiology of Dendritic Cells, Institut Pasteur - John Feder,
Associate Director of Genome Biology, Bristol-Myer-Squibb - Mats Ferm,
Senior Principle Scientist, CNSP iMed Translational Science AstraZeneca - Mark Fidock,
Group Director Biomarkers & Translational Sciences, Huntingdon Life Sciences - Bruno Flamion,
Vice-Chair of the Pharmacogenomics Working Party of the EMA - Federico Goodsaid,
Vice President, Strategic Regulatory Intelligence, Vertex Pharmaceuticals - Neil Gozzard,
Senior Director Immunology Strategy, UCB - Theresa Heath,
Senior Director, Business Development, BARC - Darren Hodgson,
Biomics Advisor, AstraZeneca - Nicholas Irving,
Neuroscience Research Portfolio Manager, Oxford University - Edwin Janssen,
Head Biomarkers and Biopharmaceuticals, Eurofins - Andreas Jeromin,
Director, Business Development and Assay Core Services, Banyan Biomarkers, Inc. - Mark Jones,
Director, Experimental Medicine (Biomarkers), New Medicines, UCB - Eric Karran,
Director of Research, Alzheimers Research UK, UK. - Morten Karsdal,
Professor, Head of R&D, Nordic Bioscience - Sebastian Krempien,
Senior Medical Advisor, Boehringer-Ingelheim - Stine Larsen,
Head of AD & PD Section, International Clinical Research – Neurology, H. Lundbeck A/S - Jennifer Li
Associate Senior Biologist, Lilly Centre for Cognitive Neuroscience, Eli Lilly and Co Ltd - Beatriz Silva Lima,
Professor University of Lisbon - Thomas Litman,
Senior Research Scientist, Molecular Biomedicine, Leo Pharma - Robin Longdin,
Client Manager, Bioanalytical Sciences, Quotient Bioresearch - Johan Luthman,
VP Neuroscience & Ophthalmology Franchise, Franchise integrator, Merck Research Laboratories - Fabio Magrini,
Senior Medical Director, MedImmune - Stuart McGregor,
Assay Development Team Leader, Randox - Gino Miele,
Biomarker Operations Director, Epistem - Phillip Monk,
Chief Scientific Officer, Synairgen Research Ltd - Kirsten Mundt,
Senior Scientific Manager, Oncology Biomarker Development, Genentech Inc - Nirmala Nanguneri,
Director & Head of the Biomarker Analysis and Informatics Unit in the Biomarker Development Department, Novartis - Valerie Nedbal,
JMP Pharmaceutical Technical Manager, SAS Institute GmbH, Germany - Sonal Patel,
Director and Head of Molecular Pharmacology, Prosidion - Stephen Pennington,
Professor of Proteomics, University College Dublin - Christopher Proctor,
CSO, British American Tobacco - Rajiv Raja,
Group Leader, Clinical Assays and Technologies Group, Oncology Biomarker Development, Genentech - Henry Rodriguez,
Director, Clinical Proteomic Technologies for Cancer, Office of the Director, National Cancer Institute - Mads Ropke,
Senior Scientst, Leo Pharma - Hugh Salter,
Associate Director, AstraZeneca - Ute Schaefer,
Professor, Head of Unit, Research Unit Experimental Neurotraumatology, Medical University Graz - Joachim Stangier,
Senior Principal Scientist, Drug Metabolism&Pharmacokinetics, Boehringer Ingelheim Pharma - Laszlo Takacs,
Founder and COO of BSI SAS, Professor, Department of Human Genetics at Medical Center of the University of Debrecen, Hungary - Thorsten Thormann,
Heading Molecular Biomedicine, Leo Pharma - Miro Venturi,
Senior Biomarker & Experimental Medicine Leader, Roche Pharma Development - Ian Wilson,
Senior Principal Scientist, Dept. of Drug Metabolism and Pharmacokinetics, AstraZeneca
